Statements (13)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:legal_case
|
| gptkbp:bfsLayer |
6
|
| gptkbp:bfsParent |
gptkb:pembrolizumab
|
| https://www.w3.org/2000/01/rdf-schema#label |
KEYNOTE-775
|
| gptkbp:indication |
endometrial cancer
|
| gptkbp:is_tested_for |
Phase 3
|
| gptkbp:launch_date |
2020-01-01
|
| gptkbp:location |
multiple countries
|
| gptkbp:participants |
overall survival
progression-free survival |
| gptkbp:sponsor |
gptkb:Merck_&_Co.
|
| gptkbp:status |
ongoing
|
| gptkbp:treatment |
gptkb:pembrolizumab
|